0(0%) Volume: 5,819,551 1:01AM EST| Market Cap | 4.52 B | P/E(ttm) | |
|---|---|---|---|
| Enterprise Value | 4.52 B | P/B | 2.13 |
OPK has been successfully added into Your Stock Email Alerts list.
You can manage your stock email alerts here.
OPK has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
GuruFocus Financial Strength Rank measures how strong a companys financial situation is. It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
| vs
industry |
vs
history |
||
|---|---|---|---|
| Cash to Debt | 1.31 |
NAS:OPK's Cash to Debt is ranked lower than
53% of the 782 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 1.69 vs. NAS:OPK: 1.31 ) Ranked among companies with meaningful Cash to Debt only. |
NAS:OPK'
s Cash to Debt Range Over the Past 10 Years
Min: 0.13 Med: 13.08 Max: No Debt Current: 1.31 |
| Equity to Asset | 0.75 |
NAS:OPK's Equity to Asset is ranked higher than
71% of the 720 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 0.63 vs. NAS:OPK: 0.75 ) Ranked among companies with meaningful Equity to Asset only. |
NAS:OPK'
s Equity to Asset Range Over the Past 10 Years
Min: -0.41 Med: 0.67 Max: 0.96 Current: 0.75 |
| F-Score: 4 |
|
| Z-Score: 4.31 |
|
| M-Score: 0.53 |
|
| WACC vs ROIC |
1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank
| vs
industry |
vs
history |
||
|---|---|---|---|
| Operating margin (%) | -2.52 |
NAS:OPK's Operating margin (%) is ranked lower than
76% of the 733 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 8.68 vs. NAS:OPK: -2.52 ) Ranked among companies with meaningful Operating margin (%) only. |
NAS:OPK'
s Operating margin (%) Range Over the Past 10 Years
Min: -31624.44 Med: -82.88 Max: -2.52 Current: -2.52 |
| Net-margin (%) | -0.80 |
NAS:OPK's Net-margin (%) is ranked lower than
73% of the 734 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 5.95 vs. NAS:OPK: -0.80 ) Ranked among companies with meaningful Net-margin (%) only. |
NAS:OPK'
s Net-margin (%) Range Over the Past 10 Years
Min: -31688.9 Med: -118.52 Max: -0.8 Current: -0.8 |
| ROE (%) | -0.49 |
NAS:OPK's ROE (%) is ranked lower than
70% of the 758 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 6.80 vs. NAS:OPK: -0.49 ) Ranked among companies with meaningful ROE (%) only. |
NAS:OPK'
s ROE (%) Range Over the Past 10 Years
Min: -3196.93 Med: -21.01 Max: -0.49 Current: -0.49 |
| ROA (%) | -0.35 |
NAS:OPK's ROA (%) is ranked lower than
68% of the 789 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 3.58 vs. NAS:OPK: -0.35 ) Ranked among companies with meaningful ROA (%) only. |
NAS:OPK'
s ROA (%) Range Over the Past 10 Years
Min: -1352.71 Med: -13.92 Max: -0.35 Current: -0.35 |
| ROC (Joel Greenblatt) (%) | -25.73 |
NAS:OPK's ROC (Joel Greenblatt) (%) is ranked lower than
77% of the 778 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 13.18 vs. NAS:OPK: -25.73 ) Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only. |
NAS:OPK'
s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -130662.93 Med: -367.75 Max: -25.73 Current: -25.73 |
| Revenue Growth (3Y)(%) | 85.10 |
NAS:OPK's Revenue Growth (3Y)(%) is ranked higher than
97% of the 602 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 5.50 vs. NAS:OPK: 85.10 ) Ranked among companies with meaningful Revenue Growth (3Y)(%) only. |
NAS:OPK'
s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0 Med: -11.6 Max: 152 Current: 85.1 |
| EBITDA Growth (3Y)(%) | 27.70 |
NAS:OPK's EBITDA Growth (3Y)(%) is ranked higher than
78% of the 570 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 10.00 vs. NAS:OPK: 27.70 ) Ranked among companies with meaningful EBITDA Growth (3Y)(%) only. |
NAS:OPK'
s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -74.6 Med: 6.6 Max: 161.2 Current: 27.7 |
| EPS Growth (3Y)(%) | -16.40 |
NAS:OPK's EPS Growth (3Y)(%) is ranked lower than
80% of the 533 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 8.20 vs. NAS:OPK: -16.40 ) Ranked among companies with meaningful EPS Growth (3Y)(%) only. |
NAS:OPK'
s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -69.4 Med: -1.6 Max: 152.4 Current: -16.4 |
| Ken Fisher 37,867 sh (+0.11%) | Paul Tudor Jones Sold Out George Soros Sold Out Murray Stahl 67,206 sh (-15.60%) Mario Gabelli 100,775 sh (-30.39%) Joel Greenblatt 30,179 sh (-74.93%) |
| Paul Tudor Jones 27,173 sh (New) Joel Greenblatt 267,485 sh (+786.33%) | Ken Fisher 37,826 sh (-0.11%) Murray Stahl 66,333 sh (-1.30%) Mario Gabelli 97,050 sh (-3.70%) |
| Jim Simons 1,412,757 sh (New) John Burbank 12,234 sh (New) George Soros 59,837 sh (New) Joel Greenblatt 535,214 sh (+100.09%) Paul Tudor Jones 36,248 sh (+33.40%) Ken Fisher 38,229 sh (+1.07%) | Mario Gabelli 97,050 sh (unchged) | Murray Stahl 60,179 sh (-9.28%) |
(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
Modify your Personalized List of Gurus, or
above to check out all the Gurus, or 
above for the stocks picks of all the institutional investment advisors (>4000) What is Peter Lynch Charts )| Industry: | Drug Manufacturers » Drug Manufacturers - Specialty & Generic NAICS: 325412 SIC: 2834 | |
|---|---|---|
| Compare: | NYSE:VRX, NYSE:MNK, NYSE:TARO, NYSE:PTHN, OTCPK:HYPMY, OTCPK:HKMPF, NAS:NBIX, NYSE:CTLT, NAS:MDCO, OTCPK:STDAF, OTCPK:DNPUF, OTCPK:IPSEY, OTCPK:IZQVF, NAS:ENDP, NAS:HZNP, NAS:AKRX, NAS:IRWD, NYSE:RDY, NAS:RDUS, NAS:PCRX » details | |
| Traded in other countries: | XCY.Germany, OPK.Israel, OPK.Mexico, |
| vs
industry |
vs
history |
||
|---|---|---|---|
| P/B | 2.13 |
OPK's P/B is ranked higher than
61% of the 753 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 2.85 vs. OPK: 2.13 ) Ranked among companies with meaningful P/B only. |
OPK'
s P/B Range Over the Past 10 Years
Min: 2.12 Med: 8.69 Max: 800 Current: 2.13 |
| P/S | 3.56 |
OPK's P/S is ranked lower than
59% of the 710 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 2.90 vs. OPK: 3.56 ) Ranked among companies with meaningful P/S only. |
OPK'
s P/S Range Over the Past 10 Years
Min: 3.54 Med: 32.5 Max: 158.13 Current: 3.56 |
| EV-to-EBITDA | 92.96 |
OPK's EV-to-EBITDA is ranked lower than
95% of the 563 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 17.04 vs. OPK: 92.96 ) Ranked among companies with meaningful EV-to-EBITDA only. |
OPK'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -146.6 Med: -34.85 Max: 539.9 Current: 92.96 |
| Current Ratio | 1.97 |
OPK's Current Ratio is ranked lower than
56% of the 760 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 2.34 vs. OPK: 1.97 ) Ranked among companies with meaningful Current Ratio only. |
OPK'
s Current Ratio Range Over the Past 10 Years
Min: 0.88 Med: 5.1 Max: 415 Current: 1.97 |
| Quick Ratio | 1.80 |
OPK's Quick Ratio is ranked higher than
52% of the 759 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 1.75 vs. OPK: 1.80 ) Ranked among companies with meaningful Quick Ratio only. |
OPK'
s Quick Ratio Range Over the Past 10 Years
Min: 0.48 Med: 4.68 Max: 415 Current: 1.8 |
| Days Inventory | 25.28 |
OPK's Days Inventory is ranked higher than
93% of the 684 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 114.19 vs. OPK: 25.28 ) Ranked among companies with meaningful Days Inventory only. |
OPK'
s Days Inventory Range Over the Past 10 Years
Min: 25.28 Med: 233.05 Max: 500.07 Current: 25.28 |
| Days Sales Outstanding | 66.84 |
OPK's Days Sales Outstanding is ranked higher than
58% of the 624 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 75.48 vs. OPK: 66.84 ) Ranked among companies with meaningful Days Sales Outstanding only. |
OPK'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 38.86 Med: 163.64 Max: 727.85 Current: 66.84 |
| Days Payable | 35.89 |
OPK's Days Payable is ranked lower than
81% of the 571 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 71.85 vs. OPK: 35.89 ) Ranked among companies with meaningful Days Payable only. |
OPK'
s Days Payable Range Over the Past 10 Years
Min: 35.89 Med: 112.55 Max: 1499.3 Current: 35.89 |
| vs
industry |
vs
history |
||
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -21.30 |
OPK's 3-Year Average Share Buyback Ratio is ranked lower than
82% of the 433 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: -4.40 vs. OPK: -21.30 ) Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only. |
OPK'
s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -146.3 Med: -14.4 Max: 0.4 Current: -21.3 |
| vs
industry |
vs
history |
||
|---|---|---|---|
| Price/Projected FCF | 2.99 | ||
| Price/Median PS Value | 0.11 |
OPK's Price/Median PS Value is ranked higher than
98% of the 641 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 1.12 vs. OPK: 0.11 ) Ranked among companies with meaningful Price/Median PS Value only. |
OPK'
s Price/Median PS Value Range Over the Past 10 Years
Min: 0.11 Med: 1.28 Max: 30 Current: 0.11 |
| Earnings Yield (Greenblatt) (%) | -1.05 |
OPK's Earnings Yield (Greenblatt) (%) is ranked lower than
73% of the 762 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 3.20 vs. OPK: -1.05 ) Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only. |
OPK'
s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -1.06 Med: 0.5 Max: 0.5 Current: -1.05 |
| Revenue (TTM) (Mil) $ | 1,222 |
|---|---|
| EPS (TTM) $ | -0.02 |
| Beta | 2.42 |
| Short Percentage of Float | 23.05% |
| 52-Week Range $ | 7.64 - 12.15 |
| Shares Outstanding (Mil) | 557.53 |
| Dec16 | Dec17 | Dec18 | Dec19 | |
|---|---|---|---|---|
| Revenue (Mil $) | 1,250 | 1,365 | 1,607 | 2,151 |
| EPS ($) | -0.08 | -0.01 | 0.26 | 0.70 |
| EPS w/o NRI ($) | -0.08 | -0.01 | 0.26 | 0.70 |
| EPS Growth Rate (3Y to 5Y Estimate) | 15.00% | |||
| Dividends Per Share ($) | ||||
| Weekly CEO Buys Highlights Feb 06 2017 |
| OPKO CEO Invests in Company Jan 30 2017 |
| Weekly CEO Buys Highlight Jan 22 2017 |
| Weekly CEO Buys Highlights Jan 09 2017 |
| Top Insider Buys Highlight for Week of Jan. 6 Jan 07 2017 |
| Weekly CEO Buys Highlights Dec 06 2016 |
| Weekly CEO Buys Highlight Oct 31 2016 |
| Weekly CEO Buys Highlights Oct 24 2016 |
| Weekly CEO Buys Highlight Oct 17 2016 |
| CEO Phillip Frost Buys OPKO Health Oct 11 2016 |
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
My Gurus
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP